TBB抑制了CK2 / PD-L1 / EGFR途径介导的瘤进展
Suning Che1, Yao Zhang1, Huihui Xu1
1School of Life Science, Jiangsu University, Zhenjiang, Jiangsu Province, 212013, China.
European journal of pharmacology
|May 1, 2025
概括
这项研究揭示了CK2诱导的PD-L1酸化如何通过稳定PD-L1和激活EGFR信号来增强癌细胞生长. 抑制CK2阻断了这种途径,为非小细胞肺癌 (NSCLC) 提供了潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 在癌细胞上编程的死亡配体1 (PD-L1) 抑制T细胞活动,促进瘤免疫逃生.
- 对于PD-L1在瘤进展中的细胞内信号作用尚未完全理解.
研究的目的:
- 研究细胞内PD-L1信号传递在非小细胞肺癌 (NSCLC) 进展中的机制.
- 确定CK2在PD-L1调节中的作用及其下游效应.
主要方法:
- 西方涂抹检测蛋白质酸化和相互作用.
- 自试验用于评估PD-L1降解.
- 细胞增殖,迁移和入侵测定.
- 在体内瘤生长研究.
- CK2耗尽和抑制的实验.
主要成果:
- 在Thr-285处,CK2酸化PD-L1,增加其稳定性并抑制自降解.
- 在T285的PD-L1酸化促进了表皮生长因子受体 (EGFR) 的结合和下游信号激活.
- 这一途径驱动NSCLC细胞的增殖,迁移,入侵和瘤生长.
- 抑制或消耗CK2可以逆转这些前瘤性影响.
结论:
- 在T285中通过CK2介导的PD-L1酸化是一种促进NSCLC进展的新机制.
- CK2/PD-L1/EGFR信号轴代表了NSCLC的潜在治疗目标.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.5K
07:36Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
6.3K
相关概念视频
Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
